Table 1 RAS-RAF-MEK-ERK activation, RAS/RAF mutation, ALK mutation, 1q21 amplification, and RASSF1A/RASD1 methylation in patients with RRMM.

Patient	pERK1/2	Amp(1q21)	KRAS codon			NRAS codon			BRAF codon			ALK codon			RASSF1A	RASD1
Patient	pERK1/2	Amp(1q21)	12	13	61	12	13	61	469	600	601	1174	1245	1275	Methylation	Methylation
1	Pos	Pos	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	UU	UU
2	Pos	Pos	WT	G(G/A)C	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	UU	UU
3	Pos	Pos	WT	WT	C(A/C)A	WT	WT	WT	WT	WT	WT	WT	WT	WT	UU	UU
4	Pos	Pos	WT	WT	WT	WT	WT	WT	WT	G(T/A)G	WT	WT	WT	WT	UU	UU
5^{^}	Pos	Neg	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	UU	UU
6	Pos	Neg	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	UU	UU
7	Pos	Pos	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	UU	UU
8	Neg	Pos	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	ND	ND	UU	UU
9	Neg	Neg	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	UU	UU
10	Neg	Pos	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	UU	UU
11	Neg	N/A	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	UU	UU
12	Pos	N/A	WT	WT	WT	WT	WT	WT	WT	WT	WT	ND	ND	ND	ND	ND
13	Pos	N/A	G(G/T)T	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	UU	UU
14	Pos	Pos	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	ND	ND
15	Pos	Pos	WT	WT	WT	WT	WT	(C/A)AA	WT	WT	WT	WT	WT	WT	UU	UU
16	Pos	N/A	G(G/A)T	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	UU	UU
17	Pos	N/A	WT	WT	WT	WT	WT	CAT	WT	WT	WT	WT	WT	WT	UU	UU

Keys: RRMM, relapsed/refractory multiple myeloma; Pos, positive; Neg, negative; N/A, not applicable; WT, wild-type; ND, not done due to insufficient DNA; ALK codon 1174/1245/1275 WT, TTC/TTC/CGA; KRAS codon 12/13/61 WT, GGT/GGC/CAA; NRAS codon 12/13/61 WT, GGT/GGT/CAA; BRAF codon 469/600/601 WT, GGA/GTG/AAA; UU, completely unmethylated; ^{^}patient in very good partial remission but had bone marrow examination because of pancytopenia, which revealed Philadelphia chromosome-negative acute lymphoblastic leukaemia with no bone marrow plasmacytosis.

Quick links

Search